HUE026231T2 - Nátriuretikus peptid alkalmazása szívelégtelenség kezelésére - Google Patents

Nátriuretikus peptid alkalmazása szívelégtelenség kezelésére Download PDF

Info

Publication number
HUE026231T2
HUE026231T2 HUE12156696A HUE12156696A HUE026231T2 HU E026231 T2 HUE026231 T2 HU E026231T2 HU E12156696 A HUE12156696 A HU E12156696A HU E12156696 A HUE12156696 A HU E12156696A HU E026231 T2 HUE026231 T2 HU E026231T2
Authority
HU
Hungary
Prior art keywords
ularitide
hours
patients
placebo
groups
Prior art date
Application number
HUE12156696A
Other languages
English (en)
Inventor
Veselin Mitrovic
Hartmut Luess
Wolf-Georg Forssmann
Markus Meyer
Klaus-Dieter Doehler
Original Assignee
Cardiorentis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardiorentis Ag filed Critical Cardiorentis Ag
Publication of HUE026231T2 publication Critical patent/HUE026231T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Claims (4)

  1. Szabadalmi igénypontok 1, yrobilaíin akut de kompenzált sziveiég telensèg kezelésében történő alkalrha--zásra, ahol az UrodHatin folyamatosan legalább egy 24 órás időtartamon át kerül beadásra,
  2. 2, Az t, igénypont szerinti Urodiiatlnf ahol az Ltrodilatin intravénás beadásra alkalmas,
  3. 3, A 2, igénypont szerinti Urodilatin, ahol az Urodilatin legalább 7,5 ng/{k'g>mtn} sebességgel; vagy 7,S ng/Cko-mm) sebességgel; vagy IS ng/íkg-mm} sebességgel; vagy 30 ng/{kgmdn) sebességgel; vagy 4S no/(kg·msn) sebességgel; vagy 60 ng/( komán} sebességgé!; vagy 1.00 ng/£kg'-rntr>} sebességgel; vagy 200 ng/(kg>n'àn} sebességgel történő beadásra alkalmas.
  4. 4, A 2.. igénypont szerinti Urodiiatln, ahoi az Ürodilatln: tartalmaz továbbá egy gyogyszerészetiieg elfogadható exdgienst vagy hordozót,
HUE12156696A 2005-04-07 2006-04-07 Nátriuretikus peptid alkalmazása szívelégtelenség kezelésére HUE026231T2 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66978605P 2005-04-07 2005-04-07
US66975105P 2005-04-08 2005-04-08
US73258505P 2005-11-01 2005-11-01

Publications (1)

Publication Number Publication Date
HUE026231T2 true HUE026231T2 (hu) 2016-06-28

Family

ID=37087353

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE12156696A HUE026231T2 (hu) 2005-04-07 2006-04-07 Nátriuretikus peptid alkalmazása szívelégtelenség kezelésére

Country Status (10)

Country Link
US (5) US7732406B2 (hu)
EP (2) EP2510942B1 (hu)
CY (1) CY1113183T1 (hu)
DK (2) DK1865976T3 (hu)
ES (2) ES2392892T3 (hu)
HU (1) HUE026231T2 (hu)
PL (2) PL2510942T3 (hu)
PT (2) PT1865976E (hu)
SI (1) SI2510942T1 (hu)
WO (1) WO2006110743A1 (hu)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3404102T1 (sl) 2004-04-21 2021-11-30 Alexion Pharmaceuticals, Inc. Konjugati za dodajanje kostem in njihova uporaba za ciljanje beljakovin na kosti
WO2006110743A1 (en) * 2005-04-07 2006-10-19 Cardiopep Pharma Gmbh Use of natriuretic peptide for treating heart failure
US7606617B2 (en) * 2006-01-31 2009-10-20 Cardiac Pacemakers, Inc. Urinalysis for the early detection of and recovery from worsening heart failure
US20080181903A1 (en) * 2006-12-21 2008-07-31 Pdl Biopharma, Inc. Conjugate of natriuretic peptide and antibody constant region
PT2171053E (pt) 2007-07-20 2014-06-25 Mayo Foundation Polipeptídeos natriuréticos
EP2078530A1 (en) * 2008-01-08 2009-07-15 Pharis Biotec GmbH Use of natriuretic peptides for treating angioedema syndromes
US8293711B2 (en) 2007-09-11 2012-10-23 Pharis Biotech Gmbh Use of natriuretic peptides for treating angioedema syndromes
EP2350118B1 (en) 2008-09-19 2016-03-30 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
US20130197188A1 (en) * 2010-03-15 2013-08-01 Wolf-Georg Forssmann Use of urodilatin for preparing a medicament for the treatment of cardiovascular, renal, pulmonary and neuronal syndromes while avoiding a rebound
WO2012088608A1 (en) 2010-12-27 2012-07-05 Enobia Canada Limited Partnership Compositions comprising natriuretic peptides and methods of use thereof
WO2012115772A2 (en) 2011-02-25 2012-08-30 Medtronic, Inc. Therapy for kidney disease and/or heart failure
WO2013016148A2 (en) * 2011-07-27 2013-01-31 Medtronic, Inc. Natriuretic peptide compositions and methods of preparation
JP2014525439A (ja) 2011-08-30 2014-09-29 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ ナトリウム利尿ポリペプチド
WO2013033675A1 (en) 2011-09-02 2013-03-07 Medtronic, Inc. Chimeric natriuretic peptide compositions and methods of preparation
US9611305B2 (en) 2012-01-06 2017-04-04 Mayo Foundation For Medical Education And Research Treating cardiovascular or renal diseases
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
TW201442722A (zh) * 2013-01-25 2014-11-16 Cardiorentis Ltd 肽於治療心血管適應症之用途
WO2016007873A1 (en) 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions and methods for treating craniosynostosis
MX2017007392A (es) 2014-12-05 2019-01-24 Alexion Pharma Inc Tratamiento de convulsiones con fosfatasa alcalina recombinante.
EP3250227A2 (en) 2015-01-28 2017-12-06 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
RU2745528C2 (ru) 2015-08-17 2021-03-26 Алексион Фармасьютикалз, Инк. Производство щелочных фосфатаз
US11229686B2 (en) 2015-09-28 2022-01-25 Alexion Pharmaceuticals, Inc. Reduced frequency dosage regimens for tissue non-specific alkaline phosphatase (TNSALP)-enzyme replacement therapy of hypophosphatasia
JP2018533571A (ja) 2015-10-30 2018-11-15 アレクシオン ファーマシューティカルズ， インコーポレイテッド 患者の頭蓋縫合早期癒合症を治療するための方法
US11065306B2 (en) 2016-03-08 2021-07-20 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
RU2754558C2 (ru) 2016-04-01 2021-09-03 Алексион Фармасьютикалз, Инк. Лечение мышечной слабости с помощью щелочных фосфатаз
EP3436020A4 (en) 2016-04-01 2019-12-25 Alexion Pharmaceuticals, Inc. METHOD FOR TREATING HYPOPHOSPHATASIE IN TEENS AND ADULTS
WO2017214130A1 (en) 2016-06-06 2017-12-14 Alexion Pharmaceuticals, Inc. Metal impact on manufacturing of alkaline phosphatases
JP7018933B2 (ja) 2016-08-18 2022-02-14 アレクシオン ファーマシューティカルズ， インコーポレイテッド 気管気管支軟化症の治療方法
EP4035659A1 (en) 2016-11-29 2022-08-03 PureTech LYT, Inc. Exosomes for delivery of therapeutic agents
KR20190129058A (ko) 2017-03-31 2019-11-19 알렉시온 파마슈티칼스, 인코포레이티드 성인 및 청소년에서 저포스파타제증 (hpp)을 치료하는 방법
CN109838289B (zh) * 2017-11-27 2022-03-15 罗伯特·博世有限公司 尿素水溶液喷射系统的回抽过程监测系统和方法
WO2019190752A1 (en) 2018-03-30 2019-10-03 Alexion Pharmaceuticals, Inc. Manufacturing of glycoproteins
US20230127487A1 (en) * 2020-03-13 2023-04-27 Mayo Foundation For Medical Education And Research Assessing and treating acute decompensated heart failure
WO2022029499A1 (en) * 2020-08-06 2022-02-10 Ads Aiphia Development Services Ag Methods of treating refractory ascites

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3346953A1 (de) 1983-12-24 1985-08-14 Organogen Medizinisch-Molekularbiologische Forschungsgesellschaft mbH, 6900 Heidelberg Cardiodilatin, ein neues peptidhormon und verfahren zu seiner herstellung
US5449751A (en) 1987-03-02 1995-09-12 Pharma Bissendorf Peptide Gmbh Cardiodilatin fragment, process for preparing same and use thereof
EP0349545B1 (en) 1987-03-02 1993-02-03 FORSSMANN, Wolf-Georg, Prof. Dr. med. New cardiodilatin fragment, process for preparing same and use thereof
US5461142A (en) 1987-11-07 1995-10-24 Pharma Bissendorf Peptide Gmbh Phosphorylated derivatives of cardiodilatin/ANF peptides
US5166191A (en) 1991-08-19 1992-11-24 Genentech, Inc. Use of relaxin in cardiovascular therapy
DE4216133A1 (de) 1992-05-15 1993-11-18 Bissendorf Peptide Gmbh Anwendung von Urodilatin bei Lungen- und Bronchialerkrankungen
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
EP0763061B1 (de) 1994-06-02 2002-10-30 Forssmann, Wolf-Georg, Prof. Dr. med. Verfahren zur herstellung von cardiodilatin-fragmenten, hochgereinigte cardiodilatin-fragmente und zwischenprodukte zu deren herstellung
US5741776A (en) 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
WO1998045329A1 (en) 1997-04-04 1998-10-15 Novo Nordisk A/S Natriuretic peptide derivatives
DE19951471A1 (de) 1999-10-26 2001-05-03 Forssmann Wolf Georg Verwendung von Urodilatin zur Behandlung chronischer Niereninsuffizienz mit Nierenrestfunktionen
US6831084B1 (en) 1999-11-12 2004-12-14 Wyeth Branched adamantyl and noradamantyl aryl- and aralkylpiperazines with serotonin 5-HT1A activity
US6407211B1 (en) 1999-12-17 2002-06-18 Mayo Foundation For Medical Education And Research Chimeric natriuretic peptides
AU1185502A (en) 2000-10-04 2002-04-15 Molecular Medicine Res Inst Methods of modulating apoptosis by administration of relaxin agonists or antagonists
KR101271635B1 (ko) 2001-12-21 2013-06-12 휴먼 게놈 사이언시즈, 인코포레이티드 알부민 융합 단백질
US20040063630A1 (en) 2002-03-18 2004-04-01 Scios, Inc. Treatment of congestive heart failure with natriuretic peptide and a diuretic
US20050113286A1 (en) 2002-03-18 2005-05-26 Schreiner George F. Methods for treating congestive heart failure
CA2504287A1 (en) 2002-11-26 2004-06-10 Nobex Corporation Natriuretic compounds, conjugates, and uses thereof
US20060008415A1 (en) 2004-06-25 2006-01-12 Protein Design Labs, Inc. Stable liquid and lyophilized formulation of proteins
WO2006041855A2 (en) 2004-10-04 2006-04-20 Nitromed, Inc. Compositions and methods using apocynin compounds and nitric oxide donors
CA2597460A1 (en) 2005-02-24 2006-08-31 Nitromed, Inc. Nitric oxide enhancing diuretic compounds, compositions and methods of use
WO2006110743A1 (en) * 2005-04-07 2006-10-19 Cardiopep Pharma Gmbh Use of natriuretic peptide for treating heart failure
WO2008073448A2 (en) 2006-12-12 2008-06-19 Amylin Pharmaceuticals, Inc. Pharmaceutical formulations and methods for making the same
US20080181903A1 (en) 2006-12-21 2008-07-31 Pdl Biopharma, Inc. Conjugate of natriuretic peptide and antibody constant region
US8293711B2 (en) 2007-09-11 2012-10-23 Pharis Biotech Gmbh Use of natriuretic peptides for treating angioedema syndromes
KR20100059859A (ko) 2007-09-11 2010-06-04 몬도바이오테크 래보래토리즈 아게 치료제로서의 ｃ형 나트륨이뇨 펩티드 단독 또는 뉴로펩티드 ａｆ와의 배합물의 용도
US20090163421A1 (en) 2007-12-19 2009-06-25 Ekr Therapeutics, Inc. Room Temperature Stable, Lyophilized Natriuretic Peptide Formulations
WO2009086126A2 (en) 2007-12-21 2009-07-09 Mayo Foundation For Medical Education And Research Natriuretic polypeptides
WO2010048308A2 (en) 2008-10-24 2010-04-29 Deborah Dickey Natriuretic polypeptides
JP2012510295A (ja) 2008-12-03 2012-05-10 ベーリンガー インゲルハイム ファーマスーティカルズ アイエヌシー． グアニル酸シクラーゼ受容体に対する抗体
CA2754408A1 (en) 2009-03-30 2010-10-14 Boehringer Ingelheim International Gmbh Fusion proteins comprising canine fc portions
US20110065676A1 (en) 2009-06-24 2011-03-17 Schering Corporation Combination therapies comprising par1 antagonists with nar agonists
US20110014180A1 (en) 2009-07-16 2011-01-20 Masafumi Koide Preparations for tissue restoration containing atrial diuretic hormone and family molecules as active ingredients; method of restoring tissue using the preparation; agents for growing, restoring, promoting growth of hair and agents for promoting restoration of skin tissue and cardiac muscle tissue containing atrial diuretic hormone family molecules as active ingredients; method of growing, restoring, promoting growth of hair by using the agents; and method of promoting restoration of skin tissue and cardiac muscle tissue
WO2011038066A2 (en) 2009-09-25 2011-03-31 Alcon Research, Ltd. Novel npr-b agonists
US8546523B2 (en) 2009-09-25 2013-10-01 Alcon Research, Ltd. NPR-B agonists
US20130197188A1 (en) 2010-03-15 2013-08-01 Wolf-Georg Forssmann Use of urodilatin for preparing a medicament for the treatment of cardiovascular, renal, pulmonary and neuronal syndromes while avoiding a rebound
CA2808907A1 (en) 2010-08-20 2012-02-23 Cerulean Pharma Inc. Therapeutic peptide-polymer conjugates, particles, compositions, and related methods

Also Published As

Publication number Publication date
SI2510942T1 (sl) 2016-01-29
US20140287999A1 (en) 2014-09-25
WO2006110743A1 (en) 2006-10-19
EP2510942A1 (en) 2012-10-17
PL2510942T3 (pl) 2016-02-29
EP1865976B1 (en) 2012-05-23
US20160324931A1 (en) 2016-11-10
US9023794B2 (en) 2015-05-05
EP2510942B1 (en) 2015-09-02
US20150224174A1 (en) 2015-08-13
PL1865976T3 (pl) 2012-11-30
US20110257099A1 (en) 2011-10-20
CY1113183T1 (el) 2016-04-13
EP1865976A4 (en) 2010-09-01
US9358271B2 (en) 2016-06-07
US20060264376A1 (en) 2006-11-23
PT1865976E (pt) 2012-08-03
EP1865976A1 (en) 2007-12-19
ES2554713T3 (es) 2015-12-22
US8710006B2 (en) 2014-04-29
DK2510942T3 (en) 2015-12-14
ES2392892T3 (es) 2012-12-14
DK1865976T3 (da) 2012-07-23
PT2510942E (pt) 2015-12-28
US7732406B2 (en) 2010-06-08

Similar Documents

Publication Publication Date Title
US9358271B2 (en) Use of natriuretic peptide for treating heart failure
Keating et al. Nesiritide: a review of its use in acute decompensated heart failure
Mitrovic et al. Effects of the renal natriuretic peptide urodilatin (ularitide) in patients with decompensated chronic heart failure: a double-blind, placebo-controlled, ascending-dose trial
JP2003534289A (ja) Ｇｌｐ−１を用いた急性冠状動静脈症候群の治療
Natali et al. Effects of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiac structure and function: a narrative review of clinical evidence
US10799561B2 (en) Method for increasing cardiac inflow by administering a compound that binds RXFP1
US9314507B2 (en) Methods of treatment of heart failure with natriuretic peptides
AU2014208851B2 (en) A natriuretic peptide, a diuretic peptide or a vaso dilatory peptide for use in methods of treating cardiovascular indications
Bettencourt Brain natriuretic peptide (nesiritide) in the treatment of heart failure
US20070082842A1 (en) Therapeutic applications for c-peptide
Predel et al. Atrial natriuretic peptide in patients with diabetes mellitus type I: effects on systemic and renal hemodynamics and renal excretory function
Kovalenko et al. The new direction in medical
US20230346889A9 (en) Treatment of acute heart failure
Unnikrishnan et al. Diabetes and
James et al. Congestive Heart Failure: Pharmacological Agents and the Potential of BType Natriuretic Peptide
Rigato et al. Diabetes and the Cardiovascular System
Perzanowski et al. Familial ventricular tachycardia with mild ventricular dysfunction: a 15 year follow up of two African American brothers with arrhythmogenic right ventricular dysplasia